SCHEMBL23218533

SCHEMBL23218533

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 3/20 0.43
TSHR P16473 1/20 0.41
PLG P00747 2/20 0.40
PLAU P00749 2/20 0.40
F11 P03951 1/20 0.40
KLKB1 P03952 1/20 0.40
F7 P08709 1/20 0.40
TPSB2 P20231 1/20 0.40
ANO1 Q5XXA6 2/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
PTGER4 P35408 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
FPR1 P21462 1/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852791 1.00 CFD (0.43) CFDTSHRPLGPLAUF11
SCHEMBL29852796 0.92 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL29852924 0.92 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23218657 0.92 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23219174 0.92 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23218528 0.91 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23218682 0.91 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23218913 0.91 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL23218540 0.91 CFD (0.42) CFDTSHRPLGPLAUF11
SCHEMBL29852750 0.91 CFD (0.42) CFDTSHRPLGPLAUF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885TSHR 1199/4885PLG 421/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885TSHR 3148/4885PLG 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.